Grant: Collaborative Research and Development Grants
University of Toronto
$93,000.00
A microfluidic blood-brain barrier model with on-chip cell barrier biosensing
EF 2019-20
Résumé
We are developing a high throughput, easy-to-use microfluidic system, used to model the interface between blood vessels and tissues for drug screening, transport studies and basic research, with a first application in blood brain barrier (BBB) modelling. Transport of drugs across the BBB is of prime interest to the pharmaceutical and biotechnology industries because the BBB is impermeable to many drugs, making neurological diseases difficult to treat. Development of neurological drugs is hampered by poor model systems, as animal models often fail to replicate human biology and current laboratory models of the BBB inadequately replicate the environment in the body, leading to poor predictive power. We have developed a microfluidic cell culture system that addresses the unmet need for advanced cell culture systems that better replicate human biology for drug development. The focus of this proposal is to improve the functionality of our system by integrating electrical sensors to monitor the quality of the BBB model directly on the platform. This is an essential feature of BBB models, but is not incorporated into any commercially-available organ-on-a-chip platform. In partnership with CellScale Biomaterials, an Ontario-based biotechnology manufacturing company, we will optimize the design of the electrodes and sensing system, integrate it into our microfluidic platform, validate its application for BBB modeling, and develop scalable manufacturing processes for commercial translation. CellScale is strongly supporting this project through both cash and in-kind contributions. They are uniquely positioned in Canada to leverage the research outputs of this project to develop products that will be market-ready within two years, contribute to the development of highly qualified personnel, generate new jobs, and contribute to economic growth in Canada as a new R&D and manufacturing centre for advanced cell culture biotechnologies.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
531083-2018
Name nom
Simmons, Craig
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
93000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:2 - 2
Partie
2
Nb partie
2
Application title
A microfluidic blood-brain barrier model with on-chip cell barrier biosensing
Keyword
NSERC
Application summary
We are developing a high throughput, easy-to-use microfluidic system, used to model the interface between blood vessels and tissues for drug screening, transport studies and basic research, with a first application in blood brain barrier (BBB) modelling. Transport of drugs across the BBB is of prime interest to the pharmaceutical and biotechnology industries because the BBB is impermeable to many drugs, making neurological diseases difficult to treat. Development of neurological drugs is hampered by poor model systems, as animal models often fail to replicate human biology and current laboratory models of the BBB inadequately replicate the environment in the body, leading to poor predictive power. We have developed a microfluidic cell culture system that addresses the unmet need for advanced cell culture systems that better replicate human biology for drug development. The focus of this proposal is to improve the functionality of our system by integrating electrical sensors to monitor the quality of the BBB model directly on the platform. This is an essential feature of BBB models, but is not incorporated into any commercially-available organ-on-a-chip platform. In partnership with CellScale Biomaterials, an Ontario-based biotechnology manufacturing company, we will optimize the design of the electrodes and sensing system, integrate it into our microfluidic platform, validate its application for BBB modeling, and develop scalable manufacturing processes for commercial translation. CellScale is strongly supporting this project through both cash and in-kind contributions. They are uniquely positioned in Canada to leverage the research outputs of this project to develop products that will be market-ready within two years, contribute to the development of highly qualified personnel, generate new jobs, and contribute to economic growth in Canada as a new R&D and manufacturing centre for advanced cell culture biotechnologies.